Christopher Marai

A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio

Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy

After Biogen's Alzheimer's Update, Wall Street Reacts

Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy

After Biogen's Alzheimer's Update, Wall Street Reacts

Inside Sarepta's Beat And Raise Q2

2 Winners From AACR Flying Under The Radar

Inside Sarepta's Beat And Raise Q2

2 Winners From AACR Flying Under The Radar

Why NICE Recommendation Is Turning Point For PTC Therapeutics Shares

Oppenheimer: Raptor Pharma Sale A 'Good Idea'

Christopher Marai Recent News

PTC Therapeutics: Oppenheimer Bull Cuts Target From $111 To $39; Jefferies Less Certain on Translarna

What You May Be Missing About PTC Therapeutics In Germany

Oppenheimer Sees 'Significant Upside Potential' In PTC Therapeutics

Keep An Eye On Sarepta Heading Into Friday's FDA Panel On Eteplirsen

How Five Prime's Bristol-Myers Partnership Helps Investors

35 Stock Ideas Oppenheimer Analysts Love Right Now

Oppenheimer Sees Translarna Approval 'Likely,' Believes PTC Is 'Catalyst Rich' Through 1H'16

PTC Therapeutics Could Quintuple In Price, Oppenheimer Predicts

Oppenheimer Is Buying Alexion Pharma On Weakness

Analysts See More Upside For Sarepta Therapeutics

This Is A Near-Term Driver At CytRX

Oppenheimer Jumps On CytRx Bandwagon

Here's Why Oppenheimer Upgraded ImmunoGen To Outperform

UPDATE: Oppenheimer Raises Price Target On Curis On Aurigene Collaboration

UPDATE: Oppenheimer Initiates Coverage on Aptose Biosciences on Positive Outlook for APTO-253